For example, Gerss et al. have shown that serum level of S100 proteins and high-sensitivity C-reactive protein assays can distinguish JIA patients who will flare within 6 months after coming off therapy from those who will go on to more stable remission43. This evidence concerns the gene CRP and juvenile idiopathic arthritis.